[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593707":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":39,"responsibleParty":114,"collaborators":25,"id":117,"slug":118,"hasResults":119,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":119,"sex":125,"minAge":126,"maxAge":25,"enrollmentInfo":127,"targetDuration":25,"studyType":130,"phases":131,"briefSummary":133,"conditions":134,"keywords":137,"overallStatus":139,"whyStopped":25,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":149},{"fullName":5,"class":6},"Shanghai 10th People's Hospital","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"Percutaneous coronary intervention using Drug-Coated Balloon (DCB)","EXPERIMENTAL",[12],"Device: Drug-Coated Balloon (DCB)",{"label":14,"type":15,"description":16,"interventionNames":17},"Either Drug-Eluting Stent (DES) implantation group","ACTIVE_COMPARATOR","Percutaneous coronary intervention using Drug-Eluting Stent (DES) implantation",[18],"Device: Drug-Eluting Stent (DES) implantation",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Drug-Coated Balloon (DCB)","Following lesion preparation (usually with a standard balloon), a drug-coated balloon is advanced to the target lesion. The balloon is inflated and maintained to allow effective drug transfer to the vessel wall.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Drug-Eluting Stent (DES) implantation","After coronary angiography identifies the target lesion, a DES is selected based on the vessel size. Post-deployment angiography is performed to confirm the result and check for complications.",[14],[31],{"name":32,"affiliation":5,"role":33},"Yidong Wei, PhD","PRINCIPAL_INVESTIGATOR",[35],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","+86-18917683409","ywei@tongji.edu.cn",[40,55,63,75,90,102],{"facility":41,"status":25,"city":42,"state":43,"zip":25,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Huaihe Hospital of Henan University","Kaifeng","Henan","China","CN",{"type":47,"coordinates":48},"Point",[49,50],114.30742,34.7986,{"lat":50,"lon":49},[53],{"name":54,"role":36,"phone":25,"phoneExt":25,"email":25},"Ruili He, MD",{"facility":56,"status":25,"city":57,"state":43,"zip":25,"country":44,"countryCode":45,"cosmosGeoPoint":58,"geoPoint":62,"contacts":25},"Luoyang Central Hospital Affiliated to Zhengzhou University","Luoyang",{"type":47,"coordinates":59},[60,61],112.43684,34.67345,{"lat":61,"lon":60},{"facility":64,"status":25,"city":65,"state":43,"zip":25,"country":44,"countryCode":45,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"The First Affiliated Hospital of Zhengzhou Uninversity","Zhengzhou",{"type":47,"coordinates":67},[68,69],113.64861,34.75778,{"lat":69,"lon":68},[72],{"name":73,"role":36,"phone":74,"phoneExt":25,"email":25},"Gang Li, PhD","+8618810531058",{"facility":76,"status":25,"city":77,"state":78,"zip":79,"country":44,"countryCode":45,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Shanghai Tenth People's Hospital","Shanghai","Shanghai Municipality","200072",{"type":47,"coordinates":81},[82,83],121.45806,31.22222,{"lat":83,"lon":82},[86],{"name":87,"role":36,"phone":88,"phoneExt":25,"email":89},"Jiachen Luo, Phd","+8618801790469","messichen@tongji.edu.cn",{"facility":91,"status":25,"city":92,"state":93,"zip":25,"country":44,"countryCode":45,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"The Second People's Hospital of Yibin","Yibin","Sichuan",{"type":47,"coordinates":95},[96,97],104.63994,28.7593,{"lat":97,"lon":96},[100],{"name":101,"role":36,"phone":25,"phoneExt":25,"email":25},"Xuechuan Dan, MD",{"facility":103,"status":25,"city":104,"state":105,"zip":25,"country":44,"countryCode":45,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Ninghai First Hospital","Ningbo","Zhejiang",{"type":47,"coordinates":107},[108,109],121.54945,29.87819,{"lat":109,"lon":108},[112],{"name":113,"role":36,"phone":25,"phoneExt":25,"email":25},"Keqiang Lin, MD",{"type":33,"investigatorFullName":115,"investigatorTitle":116,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Ya-Wei Xu","Chief Physician","100593707","dcb-for-cad-with-type-2-diabetes-100593707",false,"NCT07009938","DCB for CAD With Type 2 Diabetes","Long-Term Efficacy and Safety of Drug-Coated Balloon Angioplasty in Patients With Coronary Artery Disease and Type 2 Diabetes: A Multicenter, Prospective, Randomized Controlled Trial","DCBinT2DM","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosed CAD with ≥70% stenosis in ≥1 coronary artery confirmed by coronary angiography\n* Diagnosed type 2 diabetes (per WHO criteria)\n* Target lesion suitable for DCB (diameter 2.0-4.0 mm, length ≤40 mm)\n* Informed consent provided\n\nExclusion Criteria:\n\n* Prior coronary artery bypass surgery or PCI with complications\n* STEMI within 24 hours\n* Severe hepatic\u002Frenal dysfunction\n* Active bleeding or uncontrolled anticoagulation\n* Allergy to DCB components\n* Pregnancy or lactation\n* Psychiatric conditions limiting compliance","ALL","18 Years",{"count":128,"type":129},1000,"ESTIMATED","INTERVENTIONAL",[132],"NA","Patients with coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) often present with diffuse, complex lesions and a higher risk of in-stent restenosis after PCI. While drug-eluting stents (DES) remain the standard treatment, their long-term efficacy in diabetic patients is suboptimal. Drug-coated balloons (DCBs) offer a \"leave nothing behind\" strategy by delivering anti-proliferative drugs without permanent implants, potentially reducing restenosis and adverse events. Although DCBs have shown promise in selected lesion types, evidence in T2DM patients is limited, particularly from prospective, randomized trials. This study aims to evaluate the efficacy and safety of DCB angioplasty compared to conventional strategies in patients with CAD and T2DM, focusing on angiographic outcomes, symptom relief, and major adverse cardiovascular events.",[135,136],"Coronary Artery Disease","Diabete Type 2",[138],"coronary artery disease; type 2 diabetes mellitus; drug-coated balloon; target lesion revascularization; major adverse cardiac events","NOT_YET_RECRUITING","2025-06-06",{"date":142,"type":143},"2025-06-08","ACTUAL",{"date":145,"type":129},"2025-07-01",{"date":147,"type":129},"2028-07-01",{"name":5,"class":6},6]